

WHY DO WE NEED A MADE-IN-CANADA APPROACH TO NEW MEDICINES?



CANADA IS UNIQUE

Multiple provincial health systems with a common goal to help Canadians live longer and healthier.



30 YEARS

Canada's research ecosystem was built over the last 30 years & today is strong, multi-faceted & diverse.

CANADA'S BIOPHARMACEUTICAL INDUSTRY:

World renowned & respected.



Supports 30,000 jobs.



Contributes \$19 billion in annual economic activity.



Nearly 10% of pharmaceutical revenues are re-invested into R&D each year.



BUT PROPOSED CHANGES WILL ERODE CANADA'S HEALTHCARE AND ECONOMY.

The federal government is proposing changes to how it regulates the prices of patented medicines. These changes will compare Canada to countries with more limited access to new medicines.

THE CHANGES WILL:



Delay or restrict patient access to new medicines and reduce the number of clinical trials.



Drive investments in health research to go elsewhere.



Result in loss of quality jobs in the health sector.

WHAT CAN WE DO?

1. SUPPORT ACCESSIBLE MEDICINES FOR ALL CANADIANS.



Implement a plan to educate Canadians on current drug insurance programs.



Develop a solution for Canadians who are not eligible for insurance drug coverage



Accelerate reimbursement of new medicines by setting specific timeframes.

2. PROMOTE AFFORDABLE MEDICINES.



Find a balanced approach on pricing that ensures affordability while encouraging new medicines and investments to come to Canada.



Create a consistent process with clear timelines for price negotiations with flexible agreements.



Improve efficiencies in the supply of medicines.

3. ENCOURAGE APPROPRIATE USE OF MEDICINES.



Increase the use of big data to monitor, measure and promote better use of medicines.



Establish and link together data platforms, systems and patient registries to analyze and track prescriptions, drug utilization, genomic data and outcomes.



Standardize the appropriate use of medicines in care pathways for various diseases and conditions.

4. BOOST INVESTMENT AND INNOVATION.



Implement a comprehensive strategy to grow the life sciences industry in Canada.



Set concrete targets for investments in Canada in the context of pharmaceutical policy reform.